A medical device can be ready for patenting before it is ready for commercial launch. That distinction matters when a company begins demonstrating its technology publicly.
In Minerva Surgical, Inc. v. Hologic, Inc., the patent concerned a surgical device for endometrial ablation. Minerva demonstrated 15 working prototypes at an industry event more than a year before the patent’s earliest claimed priority date. The Federal Circuit affirmed that the asserted claims were invalid under the pre-America Invents Act public-use bar.
The device was still being developed. That did not resolve the patent issue.
The demonstrations went beyond simply displaying a product. Attendees could examine how the devices operated without confidentiality obligations, and the court found that knowledgeable observers could understand the claimed technology.
Minerva argued that continued development meant the invention was not ready for patenting. But working prototypes and sufficiently detailed technical documents established otherwise. Further refinements—and the fact that the device was not ready for FDA approval—did not change that conclusion.
The case applied an older version of U.S. patent law. Current law also treats public disclosures as potential prior art, subject to specific exceptions. A public demonstration does not automatically eliminate every patent option, but its timing and content can matter.
Practical takeaway: medical device patent strategy should be coordinated with engineering, marketing, and launch planning. Before a trade show, public demonstration, or crowdfunding campaign, review what will be disclosed and whether existing applications adequately support those features. For startups and established manufacturers alike, patent review belongs before public exposure—not just before the first commercial shipment.
Federal Circuit opinion:
Minerva Surgical, Inc. v. Hologic, Inc.
Decided February 15, 2023.
https://www.cafc.uscourts.gov/opinions-orders/21-2246.OPINION.2-15-2023_2081255.pdf







